PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1337629
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1337629
Biomarkers Market Size and Share Analysis Report by Application, Product Type, Type, Disease - Global Industry Demand Forecast to 2030
The biomarkers market was USD 54.5 billion in 2022, and it will reach USD 132.8 billion, advancing at a 11.8% CAGR, by 2030.
The growth in the industry is attributed to the surging incidence of chronic illnesses and advancements in the technologies utilized in the production of biomarkers and biomarker-based diagnostic tests, including biomarker signatures, which are enabling neurological illnesses more treatable.
In 2022, the consumables category, based on product type, held the largest share of the industry, of 70%. This is because of the increasing requirement for kit-based products for biomarker testing and the regular buying of consumables.
The software category is expected to witness the fastest growth in the years to come. This is because of the speedy acceptance of software-based methods in diagnostic labs for early and accurate disease diagnosis. Software-based biomarkers are particularly utilized in drug discovery, pharmacodynamic evaluation, and gene sequencing.
In 2022, the safety biomarkers category, based on type, held the largest biomarkers market share, of 55%, and it will remain the largest throughout this decade. This is because of the increasing number population who is at risk of cardiovascular ailments, kidney disorders, and cancer, along with increasing consciousness regarding the importance of routine health checkups.
The efficacy biomarkers category is likely to observe the fastest growth in the years to come. This is attributed to the capability of these agents to evaluate the therapeutic effectiveness of medication products, as a result, such markers are increasingly being utilized in the pharmaceutical and biotechnology sectors for drug discovery.
In 2022, the diagnostics category, based on application, accounted for the largest share in the industry, because of the advantages of biomarkers in early identification of disease, which provides the diagnostic sector an opportunity to enhance early diagnosis and advance success rates of treatment.
Whereas, the drug discovery & development category will advance at the fastest rate in the years to come. This is attributed to the increasing focus of pharmaceutical and biotechnology businesses on establishing state-of-the-art research and development facilities for the production of easier drug efficacy prediction capabilities, a quick approval process, and targeted drugs.
In 2022, North America held the largest share in the industry, of approximately 40%, and it will further advance at a robust rate throughout this decade. This is because of the increasing utilization of such markers in personalized drugs and numerous business development strategies implemented by the players, including collaborations and partnerships with major pharmaceutical and biotechnological businesses in this continent.
APAC will observe the fastest growth in the years to come. The surging incidence of cardiovascular and cancer illnesses has resulted in the increasing requirement for such agents in the continent for their detection.
With the increasing incidence of chronic illnesses and advancements in technologies, the demand for biomarkers will continue to increase in the years to come.
Table of Contents
Chapter 1. Research Scope
- 1.1. Research Objectives
- 1.2. Market Definition
- 1.3. Analysis Period
- 1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by application
- 1.4.2. Market size breakdown, by product type
- 1.4.3. Market size breakdown, by type
- 1.4.4. Market size breakdown, by disease
- 1.4.5. Market size breakdown, by region
- 1.4.6. Market size breakdown, by country
- 1.5. Market Data Reporting Unit
- 1.5.1. Value
- 1.6. Key Stakeholders
Chapter 2. Research Methodology
- 2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
- 2.2. Primary Research
- 2.3. Market Size Estimation
- 2.4. Data Triangulation
- 2.5. Currency Conversion Rates
- 2.6. Assumptions for the Study
- 2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Voice of Industry Experts/KOLs
Chapter 5. Market Indicators
Chapter 6. Industry Outlook
- 6.1. Market Dynamics
- 6.1.1. Trends
- 6.1.2. Drivers
- 6.1.3. Restraints/challenges
- 6.1.4. Impact analysis of drivers/restraints
- 6.2. Impact of COVID-19
- 6.3. Porter's Five Forces Analysis
- 6.3.1. Bargaining power of buyers
- 6.3.2. Bargaining power of suppliers
- 6.3.3. Threat of new entrants
- 6.3.4. Intensity of rivalry
- 6.3.5. Threat of substitutes
Chapter 7. Global Market
- 7.1. Overview
- 7.2. Market Revenue, by Application (2017-2030)
- 7.3. Market Revenue, by Product type (2017-2030)
- 7.4. Market Revenue, by Type (2017-2030)
- 7.5. Market Revenue, by Disease (2017-2030)
- 7.6. Market Revenue, by Region (2017-2030)
Chapter 8. North America Market
- 8.1. Overview
- 8.2. Market Revenue, by Application (2017-2030)
- 8.3. Market Revenue, by Product type (2017-2030)
- 8.4. Market Revenue, by Type (2017-2030)
- 8.5. Market Revenue, by Disease (2017-2030)
- 8.6. Market Revenue, by Country (2017-2030)
Chapter 9. Europe Market
- 9.1. Overview
- 9.2. Market Revenue, by Application (2017-2030)
- 9.3. Market Revenue, by Product type (2017-2030)
- 9.4. Market Revenue, by Type (2017-2030)
- 9.5. Market Revenue, by Disease (2017-2030)
- 9.6. Market Revenue, by Country (2017-2030)
Chapter 10. APAC Market
- 10.1. Overview
- 10.2. Market Revenue, by Application (2017-2030)
- 10.3. Market Revenue, by Product type (2017-2030)
- 10.4. Market Revenue, by Type (2017-2030)
- 10.5. Market Revenue, by Disease (2017-2030)
- 10.6. Market Revenue, by Country (2017-2030)
Chapter 11. LATAM Market
- 11.1. Overview
- 11.2. Market Revenue, by Application (2017-2030)
- 11.3. Market Revenue, by Product type (2017-2030)
- 11.4. Market Revenue, by Type (2017-2030)
- 11.5. Market Revenue, by Disease (2017-2030)
- 11.6. Market Revenue, by Country (2017-2030)
Chapter 12. MEA Market
- 12.1. Overview
- 12.2. Market Revenue, by Application (2017-2030)
- 12.3. Market Revenue, by Product type (2017-2030)
- 12.4. Market Revenue, by Type (2017-2030)
- 12.5. Market Revenue, by Disease (2017-2030)
- 12.6. Market Revenue, by Country (2017-2030)
Chapter 13. U.S. Market
- 13.1. Overview
- 13.2. Market Revenue, by Application (2017-2030)
- 13.3. Market Revenue, by Product type (2017-2030)
- 13.4. Market Revenue, by Type (2017-2030)
- 13.5. Market Revenue, by Disease (2017-2030)
Chapter 14. Canada Market
- 14.1. Overview
- 14.2. Market Revenue, by Application (2017-2030)
- 14.3. Market Revenue, by Product type (2017-2030)
- 14.4. Market Revenue, by Type (2017-2030)
- 14.5. Market Revenue, by Disease (2017-2030)
Chapter 15. Germany Market
- 15.1. Overview
- 15.2. Market Revenue, by Application (2017-2030)
- 15.3. Market Revenue, by Product type (2017-2030)
- 15.4. Market Revenue, by Type (2017-2030)
- 15.5. Market Revenue, by Disease (2017-2030)
Chapter 16. France Market
- 16.1. Overview
- 16.2. Market Revenue, by Application (2017-2030)
- 16.3. Market Revenue, by Product type (2017-2030)
- 16.4. Market Revenue, by Type (2017-2030)
- 16.5. Market Revenue, by Disease (2017-2030)
Chapter 17. U.K. Market
- 17.1. Overview
- 17.2. Market Revenue, by Application (2017-2030)
- 17.3. Market Revenue, by Product type (2017-2030)
- 17.4. Market Revenue, by Type (2017-2030)
- 17.5. Market Revenue, by Disease (2017-2030)
Chapter 18. Italy Market
- 18.1. Overview
- 18.2. Market Revenue, by Application (2017-2030)
- 18.3. Market Revenue, by Product type (2017-2030)
- 18.4. Market Revenue, by Type (2017-2030)
- 18.5. Market Revenue, by Disease (2017-2030)
Chapter 19. Spain Market
- 19.1. Overview
- 19.2. Market Revenue, by Application (2017-2030)
- 19.3. Market Revenue, by Product type (2017-2030)
- 19.4. Market Revenue, by Type (2017-2030)
- 19.5. Market Revenue, by Disease (2017-2030)
Chapter 20. Japan Market
- 20.1. Overview
- 20.2. Market Revenue, by Application (2017-2030)
- 20.3. Market Revenue, by Product type (2017-2030)
- 20.4. Market Revenue, by Type (2017-2030)
- 20.5. Market Revenue, by Disease (2017-2030)
Chapter 21. China Market
- 21.1. Overview
- 21.2. Market Revenue, by Application (2017-2030)
- 21.3. Market Revenue, by Product type (2017-2030)
- 21.4. Market Revenue, by Type (2017-2030)
- 21.5. Market Revenue, by Disease (2017-2030)
Chapter 22. India Market
- 22.1. Overview
- 22.2. Market Revenue, by Application (2017-2030)
- 22.3. Market Revenue, by Product type (2017-2030)
- 22.4. Market Revenue, by Type (2017-2030)
- 22.5. Market Revenue, by Disease (2017-2030)
Chapter 23. Australia Market
- 23.1. Overview
- 23.2. Market Revenue, by Application (2017-2030)
- 23.3. Market Revenue, by Product type (2017-2030)
- 23.4. Market Revenue, by Type (2017-2030)
- 23.5. Market Revenue, by Disease (2017-2030)
Chapter 24. South Korea Market
- 24.1. Overview
- 24.2. Market Revenue, by Application (2017-2030)
- 24.3. Market Revenue, by Product type (2017-2030)
- 24.4. Market Revenue, by Type (2017-2030)
- 24.5. Market Revenue, by Disease (2017-2030)
Chapter 25. Brazil Market
- 25.1. Overview
- 25.2. Market Revenue, by Application (2017-2030)
- 25.3. Market Revenue, by Product type (2017-2030)
- 25.4. Market Revenue, by Type (2017-2030)
- 25.5. Market Revenue, by Disease (2017-2030)
Chapter 26. Mexico Market
- 26.1. Overview
- 26.2. Market Revenue, by Application (2017-2030)
- 26.3. Market Revenue, by Product type (2017-2030)
- 26.4. Market Revenue, by Type (2017-2030)
- 26.5. Market Revenue, by Disease (2017-2030)
Chapter 27. Saudi Arabia Market
- 27.1. Overview
- 27.2. Market Revenue, by Application (2017-2030)
- 27.3. Market Revenue, by Product type (2017-2030)
- 27.4. Market Revenue, by Type (2017-2030)
- 27.5. Market Revenue, by Disease (2017-2030)
Chapter 28. South Africa Market
- 28.1. Overview
- 28.2. Market Revenue, by Application (2017-2030)
- 28.3. Market Revenue, by Product type (2017-2030)
- 28.4. Market Revenue, by Type (2017-2030)
- 28.5. Market Revenue, by Disease (2017-2030)
Chapter 29. U.A.E. Market
- 29.1. Overview
- 29.2. Market Revenue, by Application (2017-2030)
- 29.3. Market Revenue, by Product type (2017-2030)
- 29.4. Market Revenue, by Type (2017-2030)
- 29.5. Market Revenue, by Disease (2017-2030)
Chapter 30. Competitive Landscape
- 30.1. List of Market Players and their Offerings
- 30.2. Competitive Benchmarking of Key Players
- 30.3. Product Benchmarking of Key Players
- 30.4. Recent Strategic Developments
Chapter 31. Company Profiles
- 31.1. PerkinElmer AES
- 31.1.1. Business overview
- 31.1.2. Product and service offerings
- 31.1.3. Key financial summary
- 31.2. Abbott Laboratories
- 31.2.1. Business overview
- 31.2.2. Product and service offerings
- 31.2.3. Key financial summary
- 31.3. Thermo Fisher Scientific Inc
- 31.3.1. Business overview
- 31.3.2. Product and service offerings
- 31.3.3. Key financial summary
- 31.4. F. Hoffmann-La Roche Ltd
- 31.4.1. Business overview
- 31.4.2. Product and service offerings
- 31.4.3. Key financial summary
- 31.5. Bio-Rad Laboratories, Inc
- 31.5.1. Business overview
- 31.5.2. Product and service offerings
- 31.5.3. Key financial summary
- 31.6. Epigenomics AG
- 31.6.1. Business overview
- 31.6.2. Product and service offerings
- 31.6.3. Key financial summary
- 31.7. Merck KGaA
- 31.7.1. Business overview
- 31.7.2. Product and service offerings
- 31.7.3. Key financial summary
- 31.8. Agilent Technologies, Inc
- 31.8.1. Business overview
- 31.8.2. Product and service offerings
- 31.8.3. Key financial summary
- 31.9. GE Healthcare Technologies Inc
- 31.9.1. Business overview
- 31.9.2. Product and service offerings
- 31.9.3. Key financial summary
- 31.10. Siemens Healthineers AG
- 31.10.1. Business overview
- 31.10.2. Product and service offerings
- 31.10.3. Key financial summary
- 31.11. QIAGEN N.V.
- 31.11.1. Business overview
- 31.11.2. Product and service offerings
- 31.11.3. Key financial summary
- 31.12. Sino Biological, Inc
- 31.12.1. Business overview
- 31.12.2. Product and service offerings
- 31.12.3. Key financial summary
- 31.13. Meso Scale Diagnostics, LLC
- 31.13.1. Business overview
- 31.13.2. Product and service offerings
- 31.14. ENZO Biochem, Inc
- 31.14.1. Business overview
- 31.14.2. Product and service offerings
- 31.14.3. Key financial summary
- 31.15. Epistem Limited
- 31.15.1. Business overview
- 31.15.2. Product and service offerings
Chapter 32. Appendix
- 32.1. Abbreviations
- 32.2. Sources and References
- 32.3. Related Reports
